Autolus Therapeutics (AUTL) Retained Earnings (2017 - 2025)
Autolus Therapeutics posted quarterly Retained Earnings of -$5.4 million for Q4 2025, up 81.64% year-on-year from -$2.9 million in Q4 2024, and up 99.59% on a QoQ basis from -$1.3 billion in Q3 2025.
Autolus Therapeutics (AUTL) has 9 years of Retained Earnings data on file, last reported at -$5.4 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings rose 81.64% year-over-year to -$5.4 million; the trailing twelve-month figure through Dec 2025 stood at -$5.4 million (up 81.64% YoY), and the FY2025 full-year result was -$5.4 million, up 81.64% from the prior year.
- Retained Earnings for Q4 2025 stood at -$5.4 million, up from -$1.3 billion in the prior quarter.
- Across five years, Retained Earnings topped out at -$5.4 million in Q4 2025 and bottomed at -$1.3 billion in Q3 2025.
- The 5-year median for Retained Earnings is -$225.7 million (2021), against an average of -$412.2 million.
- The widest annual swing landed in 2023, when Retained Earnings slumped 4330.51%; it then soared 98.06% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$8.6 million in 2021, then plunged by 353.89% to -$38.9 million in 2022, then climbed by 25.47% to -$29.0 million in 2023, then retreated by 0.63% to -$29.2 million in 2024, then surged by 81.64% to -$5.4 million in 2025.
- The last three Retained Earnings figures came in at -$5.4 million (Q4 2025), -$1.3 billion (Q3 2025), and -$1.2 billion (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 36.42 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 130.89 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | -5.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.36 Mn |
| Sep 30, 2025 | -1.30 Bn |
| Jun 30, 2025 | -1.22 Bn |
| Mar 31, 2025 | -18.11 Mn |
| Dec 31, 2024 | -29.17 Mn |
| Sep 30, 2024 | -1.07 Bn |
| Jun 30, 2024 | -27.91 Mn |
| Mar 31, 2024 | -931.30 Mn |
| Dec 31, 2023 | -28.99 Mn |
| Sep 30, 2023 | -801.39 Mn |
| Jun 30, 2023 | -27.96 Mn |
| Mar 31, 2023 | -709.99 Mn |
| Dec 31, 2022 | -38.90 Mn |
| Sep 30, 2022 | -643.23 Mn |
| Jun 30, 2022 | -33.51 Mn |
| Mar 31, 2022 | -16.03 Mn |
| Dec 31, 2021 | -8.57 Mn |
| Sep 30, 2021 | -479.67 Mn |
| Jun 30, 2021 | -445.68 Mn |
| Mar 31, 2021 | -412.51 Mn |
| Dec 31, 2020 | -379.20 Mn |
| Sep 30, 2020 | -336.38 Mn |
| Jun 30, 2020 | -299.07 Mn |
| Mar 31, 2020 | -267.02 Mn |
| Dec 31, 2019 | -8.69 Mn |
| Sep 30, 2019 | -196.21 Mn |
| Jun 30, 2019 | -168.96 Mn |
| Dec 31, 2018 | -113.30 Mn |
| Sep 30, 2018 | -92.65 Mn |
| Sep 30, 2017 | -47.90 Mn |